BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 12902986)

  • 1. PSF-TFE3 oncoprotein in papillary renal cell carcinoma inactivates TFE3 and p53 through cytoplasmic sequestration.
    Mathur M; Das S; Samuels HH
    Oncogene; 2003 Aug; 22(32):5031-44. PubMed ID: 12902986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of PSF-TFE3 oncoprotein in the development of papillary renal cell carcinomas.
    Mathur M; Samuels HH
    Oncogene; 2007 Jan; 26(2):277-83. PubMed ID: 16832349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nuclear localization and transactivating capacities of the papillary renal cell carcinoma-associated TFE3 and PRCC (fusion) proteins.
    Weterman MJ; van Groningen JJ; Jansen A; van Kessel AG
    Oncogene; 2000 Jan; 19(1):69-74. PubMed ID: 10644981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel CLTC-TFE3 gene fusion in pediatric renal adenocarcinoma with t(X;17)(p11.2;q23).
    Argani P; Lui MY; Couturier J; Bouvier R; Fournet JC; Ladanyi M
    Oncogene; 2003 Aug; 22(34):5374-8. PubMed ID: 12917640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pediatric renal carcinoma associated with Xp11.2 translocations/TFE3 gene fusions and clinicopathologic associations.
    Altinok G; Kattar MM; Mohamed A; Poulik J; Grignon D; Rabah R
    Pediatr Dev Pathol; 2005; 8(2):168-80. PubMed ID: 15747097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PRCC, the commonest TFE3 fusion partner in papillary renal carcinoma is associated with pre-mRNA splicing factors.
    Skalsky YM; Ajuh PM; Parker C; Lamond AI; Goodwin G; Cooper CS
    Oncogene; 2001 Jan; 20(2):178-87. PubMed ID: 11313942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fusion of a novel gene, RCC17, to the TFE3 gene in t(X;17)(p11.2;q25.3)-bearing papillary renal cell carcinomas.
    Heimann P; El Housni H; Ogur G; Weterman MA; Petty EM; Vassart G
    Cancer Res; 2001 May; 61(10):4130-5. PubMed ID: 11358836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adult-onset renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusion with smooth muscle stroma and abnormal vessels.
    Kuroda N; Tamura M; Tanaka Y; Hes O; Michal M; Inoue K; Ohara M; Mizuno K; Lee GH
    Pathol Int; 2009 Jul; 59(7):486-91. PubMed ID: 19563413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transformation capacities of the papillary renal cell carcinoma-associated PRCCTFE3 and TFE3PRCC fusion genes.
    Weterman MA; van Groningen JJ; den Hartog A; Geurts van Kessel A
    Oncogene; 2001 Mar; 20(12):1414-24. PubMed ID: 11313885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma.
    Clark J; Lu YJ; Sidhar SK; Parker C; Gill S; Smedley D; Hamoudi R; Linehan WM; Shipley J; Cooper CS
    Oncogene; 1997 Oct; 15(18):2233-9. PubMed ID: 9393982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishment and characterization of a renal cell carcinoma cell line (FU-UR-1) with the reciprocal ASPL-TFE3 fusion transcript.
    Ishiguro M; Iwasaki H; Ohjimi Y; Kaneko Y
    Oncol Rep; 2004 Jun; 11(6):1169-75. PubMed ID: 15138551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The renal cell carcinoma-associated oncogenic fusion protein PRCCTFE3 provokes p21 WAF1/CIP1-mediated cell cycle delay.
    Medendorp K; van Groningen JJ; Vreede L; Hetterschijt L; Brugmans L; van den Hurk WH; van Kessel AG
    Exp Cell Res; 2009 Aug; 315(14):2399-409. PubMed ID: 19422821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay.
    Argani P; Lal P; Hutchinson B; Lui MY; Reuter VE; Ladanyi M
    Am J Surg Pathol; 2003 Jun; 27(6):750-61. PubMed ID: 12766578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impairment of MAD2B-PRCC interaction in mitotic checkpoint defective t(X;1)-positive renal cell carcinomas.
    Weterman MA; van Groningen JJ; Tertoolen L; van Kessel AG
    Proc Natl Acad Sci U S A; 2001 Nov; 98(24):13808-13. PubMed ID: 11717438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Translocation carcinomas of the kidney.
    Argani P; Ladanyi M
    Clin Lab Med; 2005 Jun; 25(2):363-78. PubMed ID: 15848741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of cyclin D1, D3, and p21 in an infantile renal carcinoma with Xp11.2 TFE3-gene fusion.
    Müller-Höcker J; Babaryka G; Schmid I; Jung A
    Pathol Res Pract; 2008; 204(8):589-97. PubMed ID: 18358634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pediatric renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion.
    Winarti NW; Argani P; De Marzo AM; Hicks J; Mulyadi K
    Int J Surg Pathol; 2008 Jan; 16(1):66-72. PubMed ID: 18203790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered expression of key cell cycle regulators in renal cell carcinoma associated with Xp11.2 translocation.
    Barroca H; Castedo S; Vieira J; Teixeira M; Müller-Höcker J
    Pathol Res Pract; 2009; 205(7):466-72. PubMed ID: 19246164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pediatric renal cell carcinoma: clinical, pathologic, and molecular abnormalities associated with the members of the mit transcription factor family.
    Ramphal R; Pappo A; Zielenska M; Grant R; Ngan BY
    Am J Clin Pathol; 2006 Sep; 126(3):349-64. PubMed ID: 16880148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal translocation carcinomas: clinicopathologic, immunohistochemical, and gene expression profiling analysis of 31 cases with a review of the literature.
    Camparo P; Vasiliu V; Molinie V; Couturier J; Dykema KJ; Petillo D; Furge KA; Comperat EM; Lae M; Bouvier R; Boccon-Gibod L; Denoux Y; Ferlicot S; Forest E; Fromont G; Hintzy MC; Laghouati M; Sibony M; Tucker ML; Weber N; Teh BT; Vieillefond A
    Am J Surg Pathol; 2008 May; 32(5):656-70. PubMed ID: 18344867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.